This study aimed to investigate the use of Plasma Rich in
Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal
ulcers. RGTA treatment was applied (one drop every two days); however, if
ulcer closure was not achieved, PRGF
eye drops treatment was added (four times/day). The time taken to reach the
ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic
corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF
eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5-9.0) months, and the follow-up period was 44.9 ± 31.5 months. The
ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious
ulcers were effective and could be a therapeutic alternative for this type of
corneal disease.